Suvretta Capital Management, LLC Cogent Biosciences, Inc. Transaction History

Suvretta Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $14.9 Million - $30.6 Million	-3,394,539 Reduced 91.48%	316,000 $2.12 Million
Q4 2023 Feb 14, 2024	BUY	$4.06 - $10.08 $2.67 Million - $6.62 Million	657,239 Added 21.53%	3,710,539 $21.8 Million
Q3 2023 Nov 14, 2023	BUY	$9.69 - $13.34 $8.08 Million - $11.1 Million	833,607 Added 37.56%	3,053,300 $29.8 Million
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.24 $3.94 Million - $5.3 Million	400,000 Added 21.98%	2,219,693 $26.3 Million
Q1 2023 May 15, 2023	BUY	$10.04 - $15.5 $83,301 - $128,603	8,297 Added 0.46%	1,819,693 $19.6 Million
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $545,322 - $759,867	-51,204 Reduced 2.75%	1,811,396 $20.9 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $11.9 Million - $21.5 Million	1,262,600 Added 210.43%	1,862,600 $27.8 Million
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $2.35 Million - $5.84 Million	600,000 New	600,000 $5.41 Million

170

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $585M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.